Pliant Therapeutics, Inc.: Focused on developing novel therapies for treatment of fibrosis. Pliant has developed a portfolio of fully-owned development candidates focused on inhibiting the TGFb pathway through integrin inhibition. The company’s lead product candidate, PLN-74809 is an oral small-molecule dual selective inhibitor of αvß6 and αvß1 integrins that is being developed in idiopathic pulmonary fibrosis (IPF), and primary sclerosing cholangitis (PSC). Positive results of a Phase 1b clinical study of PLN-7480 showed to inhibit TGF-β activation by up to 70% in alveolar macrophages collected from healthy volunteers, in a dose- and exposure-dependent manner. The second program, PLN-1474, targets advanced/end-stage liver fibrosis, and is in IND enabling studies. Pliant has a strategic licensing and collaboration agreement with Novartis covering the development and commercialization of our preclinical liver fibrosis program, PLN-1474 and up to three additional early stage integrin targets. Under the terms of the collaboration we will receive an up-front payment of $80 million, including $50 million of free cash and $30 million in equity investment commitments.
Based in...
US - Pacific
Clinical Stage
Pre-Clinical Stage
Disease Space
Rare Disease, Respiratory
Public, USA
Market Cap
500MM - 1B
Therapeutic Modalities
Small Molecule
260 Littlefield Avenue
South San Francisco
South San Francisco, CA 94080
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Top 10 Holders of Pliant Therapeutics, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
TRV GP III LLC 16.47 5,839,160 164.72 13F 6/30/20
Fidelity Management & Research Co. LLC 14.22 5,039,101 142.15 13F 6/30/20
Redmile Group LLC 9.62 3,410,657 96.21 13F 6/30/20
Eventide Asset Management LLC 8.01 2,838,125 80.06 13F 6/30/20
CHI Advisors LLC 6.51 2,305,994 65.05 13F 6/30/20
TRV GP IV LLC 6.02 2,132,867 60.17 13F 6/30/20
Citadel LP 3.48 1,232,780 34.78 13F 6/30/20
Farallon Capital Management LLC 2.40 850,801 24.00 13F 6/30/20
Cormorant Asset Management LP 1.72 611,409 17.25 13F 6/30/20
Harvard Management Co., Inc. 1.59 562,379 15.86 13F 6/30/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.